Thu, Nov 27, 2014, 2:00 PM EST - U.S. Markets closed for Thanksgiving Day

Recent

% | $
Quotes you view appear here for quick access.

China Sky One Medical, Inc. Message Board

  • serpe12 serpe12 Sep 3, 2008 7:18 AM Flag

    CSY news

    News I was expecting, "CSY will start trading on the Nasdaq Global market from sep 15."
    http://biz.yahoo.com/prnews/080902/cntu043.html?.v=1

    Now (aprox):
    pps 13,6
    eps Q2= 0,5$
    P/E<10
    Future P/E around 5 (2,46 eps estimated for 2009, I truly believe eps for 2009 will be above 3).
    Below 20 is a gift. 200 million cap. (this should be a billion $ cap company)
    Fair valuation considering eps, growth and pipeline of products as I detail below, should be around 50. PPS should be above 50 in less than a year, in fact I believe that if they get access to global markets
    in products like patches portfolio and get the expected growth internally due to Kit Tests, Patches, Oinments, and other products, this company will be a billions dollar company in 2 years time.

    Facts:
    - They are introducing a lot of new products.
    - the company is further penetrating internal and global markets.
    Growth perspectives are really very encouraging

    Kit tests division. This will experience dramatic grothw. Take a look at the link below (dated in May) that might further accelerate and increase growth in this area

    http://www.reuters.com/article/pressRele...

    this might be explosive considering:
    three products have recently started to be sold: AMI Diagnostic Kit, Human Urinary Albumin Elisa Kit and Early Pregnancy Diagnostic Kit . These diagnostic kits are being sold through drug stores, hospitals, examination stations and independent sales agents throughout the PRC. We also plan to market these products in Vietnam, Indonesia, Philippines and eventually in Africa. We expect our sales in this product category to increase in mid-2008."
    revenue from this products was <200000 $ Q2 2007, 2 million $ Q2 2008 and is expected to be 8 million $ for 2008 (based upon company projections, I believe will be even higher). As they get approval for more products and further get market penetration, this area is going to grow manifold.
    3 kit tests are expecting for approval:

    AIDS Early Examination Kit Completed clinical testing; application for manufacturing certificate submitted.

    Carcinoma Cervix Early Examination Kit Research completed and application for manufacturing certificate submitted.

    Breast Cancer Early Examination Kit Research on product formula completed; and application for production permit submitted

    Many more are under development

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • and what about their patches portfolio. Q2 Best selling product: slim patch (6 million $ in Q2 2008). Recently the company have received approval for 5 new patch products (news dated in June):

      China Sky One Medical", "CSY"), a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China, today announced that five of its products have received production permit approvals from the SFDA.

      China Sky One Medical has successfully completed pharmacokinetics studies, clinical studies and the manufacturing process for the following patches:

      Anti-smoking patch -- breaks down nicotine and other harmful chemical compounds related to cigarette smoking and reduces dependence on cigarettes;

      Scar patch -- speeds up the healing of the wounds due to trauma and surgeries and reduces the likelihood of developing permanent scars;

      Migraine patch -- provides quick pain relief for migraine sufferers while alleviating dizziness and nausea;

      Eye patch -- relaxes the muscles in the retina, which helps to reduce the likelihood of developing myopia;

      Coronary heart disease patch -- increases blood circulation in coronary arteries, which reduces the incidences of coronary heart disease and myocardial infarction.

      These patches were developed after extensive research into the market potential by China Sky One Medical's business development team. The Company has received purchase orders for some products, such as the anti-smoking patch, prior to receipt of the production permit.

      "Since most of these products utilize extracts from the natural herbs, there are not side effects for human consumption. This is especially true for anti-smoking patches. Most of the anti-smoking patches on the market contain nicotine and other chemical compounds," said Mr. Yanqin Liu, Chairman and Chief Executive Officer of China Sky One Medical, "The anti-smoking patches developed by China Sky One are extracts from natural herbs, which have no side effects."

      This series of patches plays a major role in the Company's strategy in entering into the global market. The Company currently has ten other products in development targeting the global market.

      Other products
      "total number of China Sky One's externally used products are 53 and its total marketed products are 102, giving the Company one of the most comprehensive pharmaceutical product portfolios in China. China Sky One is still aggressively seeking approval for other drugs with large market potential. By the end of 2008, the Company will have a total 34 new drugs submitted to the SFDA for approval."

      News of products recently approved that the the company is going to start selling in the second half of 2008
      http://biz.yahoo.com/prnews/080814/cnth027.html?.v=22

      http://biz.yahoo.com/prnews/080618/cnw028.html?.v=22

      http://www.pharmaceuticalonline.com/article.mvc/China-Sky-One-Medical-Obtains-SFDA-Approval-0001

      http://biz.yahoo.com/prnews/080708/cntu017.html?.v=46

      pipeline
      http://biz.yahoo.com/prnews/080710/cnth015.html?.v=50

      "At present, our ongoing research is divided into five general areas: (1) the development of an enzyme linked immune technique to prepare extraneous diagnostic kits (see table below); (2) the development of an enzyme linked gold colloid technique to prepare extraneous rapid diagnostic test strip; (3) the development of a gene recombination technique to prepare gene drug; (4) the development of a biology protein chip for various tumor diagnostic applications; and (5) the development of a cord blood stem cell bank, as more fully described in our other reports."

 

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.